Related Experiment Videos
Biomarkers in systemic lupus erythematosus.
Gabor G Illei1, Peter E Lipsky
1National Institutes of Health, Department of Health and Human Services, 10 Center Drive, Room 9S205, Bethesda, MD 20892, USA. illeig@mail.nih.gov
Current Rheumatology Reports
|September 10, 2004
Summary
Developing validated biomarkers for systemic lupus erythematosus (SLE) remains challenging. Large, multicenter studies are crucial for validating biomarkers as reliable indicators of disease susceptibility and activity.
Area of Science:
- Rheumatology
- Immunology
- Biomarker Discovery
Background:
- Systemic lupus erythematosus (SLE) lacks validated biomarkers for clinical use.
- Existing research has not yielded widely accepted diagnostic or prognostic markers.
- The need for reliable biomarkers in SLE is critical for patient management and clinical trials.
Purpose of the Study:
- To review the challenges in developing validated biomarkers for SLE.
- To summarize promising candidate biomarkers for SLE susceptibility and activity.
- To report on a multicenter initiative aimed at advancing SLE biomarker development.
Main Methods:
- Literature review of existing biomarker research in SLE.
- Analysis of difficulties in biomarker validation for clinical application.
- Summary of data on promising candidate biomarkers.
- Overview of a collaborative multicenter effort.
Main Results:
- No universally validated biomarkers for SLE currently exist.
- Significant hurdles impede the rigorous validation of candidate biomarkers.
- Several promising biomarkers for SLE susceptibility and activity have been identified.
- A multicenter initiative is underway to consolidate research efforts.
Conclusions:
- Rigorous validation in large, multicenter studies is essential for SLE biomarkers.
- Validated biomarkers are needed as surrogate endpoints in clinical studies.
- Collaborative efforts are vital to overcome current challenges in SLE biomarker development.